title: Local Injection of Lenti-BDNF at the Lesion Site Promotes M2 Macrophage Polarization and Inhibits Inflammatory Response After Spinal Cord Injury in Mice.
abstract: There is much evidence to suggest that brain-derived neurotrophic factor (BDNF) is a prominent candidate in promoting neuroprotection, axonal regeneration, and synaptic plasticity following spinal cord injury (SCI). Although some evidence indicates that BDNF has potent anti-oxidative effects and may be involved in the regulation of the immune response, the effects of BDNF in the inflammatory response during the course of secondary damage after SCI is still unclear. The present study was designed to investigate the effects of BDNF with a special focus on their effect on macrophage polarization after SCI. Adult C57 mice underwent T10 spinal cord clip compression injury and received lenti-BDNF vector injections at the epicenter of the lesion site. Four days later, total BDNF levels were greatly increased in animals that received lenti-BDNF injections. Confocal imaging showed that more than 80 % of the lenti-virus infected cells were CD11b-positive macrophages. In addition, the expression of arginase-1 and CD206 (associated with M2 macrophage phenotype) significantly increased in the animals that received lenti-BDNF injections compared with those that received lenti-EGFP injections. On the contrary, the expression of CD16/32 and inducible nitric oxide synthase (M1 phenotype marker) was down-regulated as demonstrated using flow cytometry and immunohistochemistry. Furthermore, the production of interleukin 1β and tumor necrosis factor alpha was significantly reduced whereas the levels of interleukin 10 and interleukin 13 were elevated in subjects that received lenti-BDNF vector injections. The time course of functional recovery revealed that gradual recovery was observed in the subacute phase in lenti-BDNF group, little improvement was observed in lenti-EGFP group. At the axonal level, significant retraction of the CST axons were observed in lenti-EGFP injected animals relative to lenti-BDNF group by biotinylated dextran amine tracing. In addition, compared to lenti-BDNF group markedly demyelination was observed in the lenti-EGFP group using luxol fast blue staining. In conclusion, we found that BDNF could promote the shift of M1 to M2 phenotype and ameliorate the inflammatory microenvironment. Furthermore, the roles of BDNF in immunity modulation may enhance neuroprotective effects and partially contribute to the locomotor functional recovery after SCI.
authors.affiliation: Graduate School, The Third Military Medical University, Chongqing, 400038, China, eliteDr@163.com.
authors.forename: Xin-Chao
authors.initials: XC
authors.lastname: Ji
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Dang
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Gao
authors.forename: Zhao-Tao
authors.initials: ZT
authors.lastname: Wang
authors.forename: Mou
authors.initials: M
authors.lastname: Gao
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.forename: Hong-Tian
authors.initials: HT
authors.lastname: Zhang
authors.forename: Ru-Xiang
authors.initials: RX
authors.lastname: Xu
mesh_terms: D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage* / Q000235:genetics* / Q000494:pharmacology; D016764:Cell Polarity / Q000187:drug effects; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D015552:Injections, Intralesional; D007278:Injections, Spinal; D016086:Lentivirus / Q000235:genetics; D008262:Macrophage Activation / Q000187:drug effects / Q000235:genetics; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009187:Myelitis / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D013119:Spinal Cord Injuries / Q000235:genetics / Q000473:pathology / Q000628:therapy*
chemical_list: D019208:Brain-Derived Neurotrophic Factor
references.citation: J Neurosci. 2009 Oct 28;29(43):13435-44
references.pmid: 19864556
references.citation: Curr Opin Neurol. 2011 Dec;24(6):577-83
references.pmid: 21968547
references.citation: Curr Opin Neurobiol. 2000 Jun;10(3):381-91
references.pmid: 10851172
references.citation: Exp Neurol. 2012 Dec;238(2):254-64
references.pmid: 22982152
references.citation: J Neurosci. 2008 Jul 2;28(27):6836-47
references.pmid: 18596159
references.citation: PLoS One. 2013 May 28;8(5):e64755
references.pmid: 23724091
references.citation: J Immunol. 2012 Oct 1;189(7):3439-48
references.pmid: 22925925
references.citation: Neurotherapeutics. 2014 Jul;11(3):636-50
references.pmid: 24853068
references.citation: Oncol Rep. 2008 Nov;20(5):1201-6
references.pmid: 18949422
references.citation: J Neurotrauma. 2006 May;23(5):635-59
references.pmid: 16689667
references.citation: PLoS One. 2013;8(2):e54841
references.pmid: 23418431
references.citation: Stroke. 2008 Mar;39(3):1012-21
references.pmid: 18239176
references.citation: J Clin Invest. 2012 Mar;122(3):787-95
references.pmid: 22378047
references.citation: Exp Neurol. 2012 May;235(1):162-73
references.pmid: 22227059
references.citation: J Neuroinflammation. 2012 Feb 27;9:40
references.pmid: 22369693
references.citation: Mol Neurobiol. 2013 Jun;47(3):1011-9
references.pmid: 23321790
references.citation: Exp Neurol. 2010 May;223(1):128-42
references.pmid: 19646438
references.citation: Curr Pharm Des. 2005;11(10):1223-36
references.pmid: 15853679
references.citation: Exp Neurol. 2013 Sep;247:101-9
references.pmid: 23583688
references.citation: Exp Neurol. 1995 Apr;132(2):220-8
references.pmid: 7789460
references.citation: Brain. 2007 Aug;130(Pt 8):2199-210
references.pmid: 17557778
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5779-84
references.pmid: 9576961
references.citation: Front Neurol. 2013 Nov 19;4:187
references.pmid: 24312075
references.citation: Nat Rev Immunol. 2011 Oct 25;11(11):750-61
references.pmid: 22025054
references.citation: Brain. 2010 Aug;133(Pt 8):2248-63
references.pmid: 20826430
references.citation: Exp Neurol. 2008 Feb;209(2):294-301
references.pmid: 17617407
references.citation: Amino Acids. 1998;14(1-3):121-9
references.pmid: 9871451
references.citation: J Neurosci. 2008 Sep 17;28(38):9330-41
references.pmid: 18799667
references.citation: Nat Med. 2006 Jul;12(7):829-34
references.pmid: 16783372
references.citation: J Neurotrauma. 2012 May 20;29(8):1614-25
references.pmid: 22233298
references.citation: Neuroscience. 2011 Jan 13;172:398-405
references.pmid: 21034794
references.citation: J Neurosci. 2012 Oct 3;32(40):13956-70
references.pmid: 23035104
references.citation: Immunity. 2010 May 28;32(5):593-604
references.pmid: 20510870
references.citation: J Neuropathol Exp Neurol. 2002 Feb;61(2):142-53
references.pmid: 11853017
references.citation: Immunity. 2013 Jan 24;38(1):66-78
references.pmid: 23177319
references.citation: Immunity. 2014 Jul 17;41(1):14-20
references.pmid: 25035950
references.citation: J Neurochem. 1999 Aug;73(2):521-31
references.pmid: 10428047
references.citation: Eur J Neurosci. 2012 Jan;35(2):221-32
references.pmid: 22211901
references.citation: J Neurosci. 1997 Dec 15;17(24):9583-95
references.pmid: 9391013
references.citation: J Neurotrauma. 2002 Feb;19(2):175-90
references.pmid: 11893021
references.citation: Science. 2009 Oct 23;326(5952):592-6
references.pmid: 19833921
references.citation: Neuroreport. 2004 May 19;15(7):1163-6
references.pmid: 15129166